These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35980949)

  • 1. Various impacts of driver mutations on the PD-L1 expression of NSCLC.
    Chu CH; Huang YH; Lee PH; Hsu KH; Chen KC; Su KY; Yu SL; Tseng JS; Yang TY; Chang GC
    PLoS One; 2022; 17(8):e0273207. PubMed ID: 35980949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between Programmed Death Ligand-1(PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype.
    Pandey RK; Shukla S; Husain N; Islam MH; Hadi R; Kant Tripathi S; Singhal A
    Asian Pac J Cancer Prev; 2022 Jan; 23(1):131-142. PubMed ID: 35092381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic role of PD-1, PD-L1, ALK, and ROS1 proteins expression in non-small cell lung carcinoma patients from Egypt.
    Bahnassy AA; Ismail H; Mohanad M; El-Bastawisy A; Yousef HF
    J Egypt Natl Canc Inst; 2022 May; 34(1):23. PubMed ID: 35644823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of PD-L1 expression with driver gene mutations and clinicopathological characteristics in non-small cell lung cancer: A real-world study of 10 441 patients.
    Ruiz G; Enrico D; Mahmoud YD; Ruiz A; Cantarella MF; Leguina L; Barberis M; Beña A; Brest E; Starapoli S; Mendoza Bertelli A; Tsou F; Pupareli C; Coppola MP; Scocimarro A; Sena S; Levit P; Perfetti A; Aman E; Girotti MR; Arrieta O; Martín C; Salanova R
    Thorac Cancer; 2024 Apr; 15(11):895-905. PubMed ID: 38456253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
    Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
    Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The correlation between programmed death-ligand 1 expression and driver gene mutations in NSCLC.
    Yang H; Chen H; Luo S; Li L; Zhou S; Shen R; Lin H; Xie X
    Oncotarget; 2017 Apr; 8(14):23517-23528. PubMed ID: 28423587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Common driver mutations and programmed death-ligand 1 expression in advanced non-small cell lung cancer in smokers and never smokers.
    Liam CK; Yew CY; Pang YK; Wong CK; Poh ME; Tan JL; Soo CI; Loh TC; Chin KK; Munusamy V; Liam YS; Ibrahim NH
    BMC Cancer; 2023 Jul; 23(1):659. PubMed ID: 37452277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between PD-L1 expression and driver gene mutations in non-small cell lung cancer patients: correlation with clinical data.
    Karatrasoglou EA; Chatziandreou I; Sakellariou S; Stamopoulos K; Kavantzas N; Lazaris AC; Korkolopoulou P; Saetta AA
    Virchows Arch; 2020 Aug; 477(2):207-217. PubMed ID: 31989260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The efficacy and prognostic factors of immunotherapy in advanced non-small cell lung cancer patients with different driver gene mutations].
    Ma SX; Ma N; Han J; He Z; Wang L; Wang Q
    Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(13):922-929. PubMed ID: 35385963
    [No Abstract]   [Full Text] [Related]  

  • 10. [A Real-world Study on the Assessment of Pathological Characteristics and Targeted Therapeutic Effect of Non-small Cell Lung Cancer Patients with Positive Driving Genes and High PD-L1 Expression].
    Zhang H; Yang X; Li K; Wang J; Lv J; Li X; Zhang X; Qin N; Zhang Q; Wu Y; Ma L; Gai F; Hu Y; Zhang S
    Zhongguo Fei Ai Za Zhi; 2021 Feb; 24(2):78-87. PubMed ID: 33478196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation.
    Zhang B; Zeng J; Zhang H; Zhu S; Wang H; He J; Yang L; Zhou N; Zu L; Xu X; Song Z; Xu S
    Front Immunol; 2022; 13():974581. PubMed ID: 36159860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmed death-ligand 1 expression and its associations with clinicopathological features, prognosis, and driver oncogene alterations in surgically resected lung adenocarcinoma.
    Takamochi K; Hara K; Hayashi T; Kohsaka S; Takahashi F; Suehara Y; Suzuki K
    Lung Cancer; 2021 Nov; 161():163-170. PubMed ID: 34600407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes.
    He Y; Yu H; Rozeboom L; Rivard CJ; Ellison K; Dziadziuszko R; Suda K; Ren S; Wu C; Hou L; Zhou C; Hirsch FR
    J Thorac Oncol; 2017 May; 12(5):814-823. PubMed ID: 28132868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 expression in ROS1-rearranged non-small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1.
    Lee J; Park CK; Yoon HK; Sa YJ; Woo IS; Kim HR; Kim SY; Kim TJ
    Thorac Cancer; 2019 Jan; 10(1):103-110. PubMed ID: 30475455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib.
    Yang CY; Liao WY; Ho CC; Chen KY; Tsai TH; Hsu CL; Liu YN; Su KY; Chang YL; Wu CT; Liao BC; Hsu CC; Hsu WH; Lee JH; Lin CC; Shih JY; Yang JC; Yu CJ
    Oncologist; 2020 Aug; 25(8):702-711. PubMed ID: 32386255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer.
    Kim H; Kwon HJ; Park SY; Park Y; Park E; Chung JH
    PLoS One; 2018; 13(6):e0198634. PubMed ID: 29856861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
    Rangachari D; VanderLaan PA; Shea M; Le X; Huberman MS; Kobayashi SS; Costa DB
    J Thorac Oncol; 2017 May; 12(5):878-883. PubMed ID: 28104537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
    Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
    Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
    [No Abstract]   [Full Text] [Related]  

  • 19. Evaluation of the Molecular Landscape in PD-L1 Positive Metastatic NSCLC: Data from Campania, Italy.
    Pisapia P; Iaccarino A; De Luca C; Acanfora G; Bellevicine C; Bianco R; Daniele B; Ciampi L; De Felice M; Fabozzi T; Formisano L; Giordano P; Gridelli C; Ianniello GP; Libroia A; Maione P; Nacchio M; Pagni F; Palmieri G; Pepe F; Russo G; Salatiello M; Santaniello A; Scamarcio R; Seminati D; Troia M; Troncone G; Vigliar E; Malapelle U
    Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib.
    Chen Y; Jiang B; He Y; Zhang C; Zhou W; Fang C; Gu D; Zhang M; Ji M; Shi J; Yang X
    BMC Med Genomics; 2022 Jun; 15(1):141. PubMed ID: 35739536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.